Scientists have discovered new cancer immunotherapy based on nanobiology

Scientists from institutions such as Mount Sinai Hospital have made significant progress in the development of new cancer immunotherapy by pairing nano-bio-micromaterials and therapeutic groups produced by bioengineering natural molecules to eliminate tumor cells.
researchers say the nanobiological immunotherapy targets the bone marrow, where part of the immune system forms, and activates the body's trained immunity, a process that reprograms bone marrow pregenitor cells to produce trained congenital immune cells that inhibit cancer progression, and cancer cells often protect themselves from the host immune system with the help of the body's immunosuppressive cells.
researchers believe that trained immunity can be safely and successfully used as a cancer treatment, and that they have been tested in animal models, including melanoma mouse models, and are now actively moving toward clinical trials.
Immunotherapy is part of a standard cancer treatment that exposes the host immune system to cancer, but there are limitations, such as immuno-checkpoint inhibitor therapy, which is effective only for a limited number of patients and can have serious therapeutic side effects. In the
study, researchers developed a new type of anti-cancer therapy, which they say can be trained as an independent anti-cancer therapy and can be used in combination with checkpoint inhibitor drugs. Professor Willem J. Mulder, a researcher at
, said that in the study, not only did the powerful anti-cancer effects of nanobiological immunotherapy be observed, but the work also led to the development and preclinical evaluation of new immunotherapy based on high biocompaciate nanomaterials, which are critical for effectively training the body's immunity and developing new therapies that can be used quickly in cancer patients.
the study changed the rules in the field of immunotherapy research, and later researchers will continue to delve into developing more effective new treatments for cancer, the researchers said.
Ministry of Science and Technology Source: Ministry of Science and Technology Copyright Notice: All text, images and audio and video materials on this website that indicate "Source: Metz Medicine" or "Source: MedSci Original" are owned by Metz Medical and may not be reproduced by any media, website or individual without authorization.
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
at the same time reproduced content does not represent the position of this site.
leave a message here